Company / Cash & Equivalents
Sana Biotechnology, Inc. Cash & Equivalents History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$127.6M
FY2024
5-year range
$124.8M / $253.0M
FY2020-FY2024
Trend
-4.5%
vs FY2023
Sector context
#126 of 207
Health Care
What the data says
At $128M, Sana Biotechnology, Inc.'s cash & equivalents ranks #126 of 207 in the Health Care sector. Cash & Equivalents has declined for 3 consecutive years, from $253M in FY2021 to $128M in FY2024.
Based on SEC 10-K filings.
$128M in FY2024 with a 3-year CAGR of -20.4%.
Declined from $177M to $128M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -20.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#126 of 207 in Health CareTop 61% of 207This company $127.6M Sector average $669.5M
▼
-80.9% below sector average
Key checks
Key Insights
- Sana Biotechnology, Inc.'s cash & equivalents has declined for 3 consecutive years.
- 3-year CAGR of -20.4%, indicating a declining trend.
- In FY2024, cash & equivalents decreased 4.5% year-over-year.
- Ranks #126 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $127.6M | -4.5% |
| FY2023 | $133.5M | -24.5% |
| FY2022 | $176.8M | -30.1% |
| FY2021 | $253.0M | +102.7% |
| FY2020 | $124.8M | - |
| FY2019 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026